Long-Term Data Shows Sustained Skin Clearance in Psoriasis with FDA-Approved Biologic
Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.
Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.
The partnership provides HIPAA-compliant insights and automated retention campaigns by combining lead, patient, and EMR data into a single dashboard.